Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
| Condition | Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma, Head and Neck Cancer Stage III |
|---|---|
| Phase | Phase 2 |
| Sponsor | University of California, San Diego |
| Status | Completed |
| Enrollment | 7 participants |
| Interventions | Pembrolizumab, Tadalafil |
| Start date | Apr 7, 2020 |
| Completion date | Apr 16, 2022 |
| Results posted | Feb 12, 2026 |
Summary
This study will examine the combination of pembrolizumab and tadalafil for safety and efficacy in advanced head and neck cancer.
Rate of Dose Limiting Toxicity (DLT)
| Tadalafil and Pembrolizumab | 1 Participants |
|---|
Overall Survival (OS)
| Tadalafil and Pembrolizumab | 3 Participants |
|---|
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- Safety and Efficacy of tPBM for Epileptiform Activity in Autism — Richard Frye
- Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Th — SK Life Science, Inc.
- Sphenopalatine Ganglion Nerve Block vs. Elavil for Treatment of Transformed Migraines — Rutgers, The State University of New Jersey
- Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagno — University of Virginia
- A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or — Takeda
- Maintenance TMS in Treatment Resistant Depression — Austin Messner